trial

Early Detection and Intervention for the Prevention of Psychosis

NCTId NCT00531518
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 292 (actual)
Sponsored by MaineHealth
Primary completion 2013-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
292 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
Single
Start
2007-10
Primary completion
2013-05
Eligibility
ALL · 12 Years · 25 Years

Interventions & indications

Drugs
AripiprazolePsychoeducational multifamily group treatmentSupported employment and education

Sponsors

MaineHealthLead Sponsor
Robert Wood Johnson FoundationCollaborator

Investigators

1
William R. McFarlane, M.D.Principal Investigator

Sites

6 total
Sacramento, United StatesPortland, United StatesAnn Arbor, United StatesAlbuquerque, United StatesGlen Oaks, United StatesSalem, United States

Facts & assertions

4 sourced
Enrollment
292
Phase
NA
Primary Completion Date
2013-05
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Psychoeducational multifamily group treatment
drug
Supported employment and education
drug
lead_sponsor
MaineHealth
company
collaborator
Robert Wood Johnson Foundation
company
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
Depressive Disorder, Major
indication
investigator
William R. McFarlane, M.D.
person